Aaron Klein | Brookings brookings.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from brookings.edu Daily Mail and Mail on Sunday newspapers.
WAYNE, Pa., July 20, 2023 (GLOBE NEWSWIRE) Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases
Aaron Klein brookings.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from brookings.edu Daily Mail and Mail on Sunday newspapers.
Notably, Center City and suburban biotech and pharma companies started the new year off with millions invested ahead of clinical trials and development.
Troutman Pepper client Palvella Therapeutics, Inc., a late clinical-stage biopharmaceutical company, recently announced the initial closing of its Series D financing of up to $37.7 million.